Загрузка...
Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors
Although the clinical development of immune checkpoint inhibitors (ICIs) therapy has ushered in a new era of anti-tumor therapy, with sustained responses and significant survival advantages observed in multiple tumors, most patients do not benefit. Therefore, more and more attention has been paid to...
Сохранить в:
| Опубликовано в: : | Biomark Res |
|---|---|
| Главные авторы: | , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
BioMed Central
2020
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7450548/ https://ncbi.nlm.nih.gov/pubmed/32864131 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40364-020-00209-0 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|